NCT01436565View on ClinicalTrials.gov

A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Solid Tumor Cancers
Interventions
DRUG

MM-121 (SAR256212)

"Pharmaceutical form:solution~Route of administration: Intravenous"

DRUG

SAR245408

"Pharmaceutical form:tablet~Route of administration: oral"

Trial Locations (3)

37232

Investigational Site Number 840002, Nashville

02115

Investigational Site Number 840001, Boston

Investigational Site Number 840101, Brookline

Sponsors

Lead Sponsor

Sanofi

Collaborators (1)

Merrimack Pharmaceuticals
All Listed Sponsors
collaborator

Merrimack Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY

NCT01436565 - A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers | Biotech Hunter | Biotech Hunter